Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE Conclusions MYC-amplified neuroblastomas are extremely rare and seem to present with distinct clinicopathological features. 29426276 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 GeneticVariation disease BEFREE Stage 4 NBL with MYC-N amplification and 1p36 deletion was diagnosed in an 11 months old girl. 31441848 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. 31406244 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Specific inhibition of hyperactive rRNA synthesis and protein translation was shown to be an effective way to suppress MYC/MYCN protein expression and neuroblastoma growth. 29464082 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma. 29379199 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE These data suggest that epigenetic and posttranslational inhibition of MYC/MYCN-driven pathways may have significant clinical efficacy against neuroblastoma. 30153557 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE N6,2'-O-dibutyryladenosine 3':5'cyclic monophosphate (Bt2cAMP) inhibited neuroblastoma cell growth by inhibiting c-MYC and HDAC8 expression and activating caspase 3. 30237861 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE We found that MELK is a direct transcription target of MYCN and MYC in NB, and MYCN increases MELK expression via direct promoter binding. 29416794 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE Our study implicates the role of BORIS/CTCFL in maintenance of stemness and in transition from mesenchymal to epithelial state in MYC amplified neuroblastoma IMR-32 cells. 28104398 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Analysis of human neuroblastoma tumor specimens revealed that MYC up-regulation correlates with markers of TAM infiltration. 29207662 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Although MYC translocations define Burkitt lymphoma and MYC protein expression is a poor prognostic factor in undifferentiated neuroblastomas, the distribution of MYC protein (c-MYC) across other pediatric small round blue cell tumors (SRBCT) has not been well characterized. 28521631 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both <i>in vitro</i> and <i>in vivo</i> Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.<b>Conclusions:</b> The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma. 28270499 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE This hypothesis-driven systems bioinformatics work offered novel insights into the PRC2-mediated tumor cell growth and differentiation in neuroblastoma, which may exert oncogenic effects together with MYC regulation. 28984200 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE These data highlight a novel route for cell death induction by PARP inhibitors and support their introduction, together with CHK1 inhibitors, in therapeutic approaches for neuroblastomas with high MYC(N) activity. 28394338 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. 29207623 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. 28684529 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis. 26373717 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival. 26434591 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Here, we found miR-1303 was upregulated in NB cells and tissues, miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect. mechanism analysis suggested glycogen synthase kinase 3 beta (GSK3β) and secreted frizzled-related protein 1 (SFRP1) were the target of miR-1303, luciferase assay revealed miR-1303 directly bound to the 3'UTR of GSK3β and SFRP1. miR-1303 increased expression of MYC and CyclinD1, and decreased the expression of p21 and p27, and further demonstrated miR-1303 promotes NB proliferation. 27434867 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 GeneticVariation disease BEFREE Amplification of the MYCN oncogene, a member of the MYC family of transcriptional regulators, is one of the most powerful prognostic markers identified for poor outcome in neuroblastoma, the most common extracranial solid cancer in childhood. 27448979 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma. 27012811 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. 27197232 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 Biomarker disease BEFREE Immunostaining for MYCN and MYC protein was performed on 357 undifferentiated/poorly differentiated neuroblastomas. 26035700 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification. 25475555 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.600 AlteredExpression disease BEFREE In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells. 25880909 2015